Advice

Following an abbreviated submission

olmesartan medoxomil/amlodipine as besilate (Sevikar) is accepted for use in NHS Scotland for treatment of essential hypertension in patients whose blood pressure is not adequately controlled on olmesartan medoxomil or amlodipine monotherapy.

In patients for whom concomitant use of these medicines is appropriate it allows administration of a single tablet at a lower or modestly increased cost compared to the individual components (depending on dose). Angiotensin receptor blockers are an alternative to ACE inhibitors where these are not tolerated. This fixed dose combination is one of many options for the treatment of hypertension, many of which are less expensive.

Download detailed advice45KB (PDF)

Download

Medicine details

Medicine name:
olmesartan medoximil / amlodipine besilate (Sevikar)
SMC ID:
574/09
Indication:
For treatment of essential hypertension
Pharmaceutical company
Daiichi Sankyo UK Ltd
BNF chapter
Cardiovascular system
Submission type
Abbreviated
Status
Accepted
Date advice published
12 October 2009